177 related articles for article (PubMed ID: 38533514)
1. Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report.
Zhao K; Li Q; Li P; Liu T; Liu X; Zhu F; Zhang L
Front Immunol; 2024; 15():1303310. PubMed ID: 38533514
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.
Zhao Y; Xu H; Zhang M; Li L
Front Genet; 2022; 13():881345. PubMed ID: 35601491
[No Abstract] [Full Text] [Related]
3. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the enigma of B cells in diffuse large B-cell lymphoma: unveiling cancer stem cell-like B cell subpopulation at single-cell resolution.
Liu F; Zheng J; Yang G; Pan L; Xie Y; Chen S; Tuo J; Su J; Ou X; Liu R
Front Immunol; 2023; 14():1310292. PubMed ID: 38149239
[TBL] [Abstract][Full Text] [Related]
5. Novel agents in relapsed/refractory diffuse large B-cell lymphoma.
Varma G; Goldstein J; Advani RH
Hematol Oncol; 2023 Jun; 41 Suppl 1():92-106. PubMed ID: 37294966
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Pathologically complete remission to combination of invariant NK T cells and anti-CD20 antibody in a refractory HIV+ diffuse large B-cell lymphoma patient.
Wang J; Zhang R; Ding X; Jin Y; Qin R; Xia B; Liao Q; Hu H; Song W; Wang Z; Zhang X; Xu J
Immunotherapy; 2022 Jun; 14(8):599-607. PubMed ID: 35443802
[TBL] [Abstract][Full Text] [Related]
9. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
Brooks TR; Caimi PF
Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
[TBL] [Abstract][Full Text] [Related]
10. Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.
Shi Y; Ding W; Gu W; Shen Y; Li H; Zheng Z; Zheng X; Liu Y; Ling Y
J Leukoc Biol; 2022 Dec; 112(6):1633-1648. PubMed ID: 36040107
[TBL] [Abstract][Full Text] [Related]
11. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Yang X; Min X; He W
Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
[TBL] [Abstract][Full Text] [Related]
13. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
15. Application of next-generation sequencing in diffuse large B-cell lymphoma.
Wang Y; Jia S; Cao X; Ge S; Yu K; Chen Y
Pharmacogenomics; 2023 Jan; 24(1):59-68. PubMed ID: 36661028
[TBL] [Abstract][Full Text] [Related]
16. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma.
Higashi M; Tokuhira M; Fujino S; Yamashita T; Abe K; Arai E; Kizaki M; Tamaru J
Leuk Lymphoma; 2016; 57(1):161-6. PubMed ID: 25860238
[TBL] [Abstract][Full Text] [Related]
17. Spatially-resolved transcriptomics reveal macrophage heterogeneity and prognostic significance in diffuse large B-cell lymphoma.
Liu M; Bertolazzi G; Sridhar S; Lee RX; Jaynes P; Mulder K; Syn N; Hoppe MM; Fan S; Peng Y; Thng J; Chua R; Jayalakshmi ; Batumalai Y; De Mel S; Poon L; Chan EHL; Lee J; Hue SS; Chang ST; Chuang SS; Chandy KG; Ye X; Pan-Hammarström Q; Ginhoux F; Chee YL; Ng SB; Tripodo C; Jeyasekharan AD
Nat Commun; 2024 Mar; 15(1):2113. PubMed ID: 38459052
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
Li XY; Wu JC; Liu P; Li ZJ; Wang Y; Chen BY; Hu CL; Fei MY; Yu PC; Jiang YL; Xu CH; Chang BH; Chen XC; Zong LJ; Zhang JY; Fang Y; Sun XJ; Xue K; Wang L; Chen SB; Jiang SY; Gui AL; Yang L; Gu JJ; Yu BH; Zhang QL; Wang L
Leukemia; 2023 Jan; 37(1):164-177. PubMed ID: 36352191
[TBL] [Abstract][Full Text] [Related]
19. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
20. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
